<SEC-DOCUMENT>0000200406-13-000077.txt : 20130620
<SEC-HEADER>0000200406-13-000077.hdr.sgml : 20130620
<ACCEPTANCE-DATETIME>20130620160959
ACCESSION NUMBER:		0000200406-13-000077
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130617
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130620
DATE AS OF CHANGE:		20130620

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JOHNSON & JOHNSON
		CENTRAL INDEX KEY:			0000200406
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				221024240
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			1212

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03215
		FILM NUMBER:		13924585

	BUSINESS ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
		BUSINESS PHONE:		732-524-2455

	MAIL ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a201306178-karagon.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using WebFilings 1 -->
		<!-- Copyright 2008-2013 WebFilings LLC. All Rights Reserved -->
		<title>2013 0617 8-K Aragon</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sE9E317286A854683196D5CF3410D35C4"></a><div></div><br><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WASHINGTON, DC 20549</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 8-K</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Pursuant to Section 13 or 15(d) of the</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Date of report (Date of earliest event reported):&#160; June 17, 2013</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;"><img src="form8ktemplateimage1.gif" style="height:46px;width:181px;"></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="31%"></td><td width="38%"></td><td width="31%"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New Jersey</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I-3215</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22-1024240</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or Other Jurisdiction of Incorporation)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission File Number)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(IRS Employer Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">One Johnson &amp; Johnson Plaza, New Brunswick, New Jersey&#160;&#160;08933</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of Principal Executive Offices) (Zip Code)</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Registrant&#8217;s telephone number, including area code:&#160;&#160;732-524-0400</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><a name="sE9E317286A854683196D5CF3410D35C4"></a><div></div><br><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8.01  Other Events. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 17, 2013, the Registrant announced a definitive agreement to acquire Aragon Pharamceuticals, Inc., a privately-held, pharmaceutical discovery and development company focused on drugs to treat hormonally-driven cancers. Under the terms of the agreement, the Registrant will make an upfront cash payment of $650 million, plus additional contingent payments of up to $350 million based on reaching predetermined milestones.&#160; The transaction is expected to close in the third quarter of 2013</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to closing, Aragon will transfer all assets other than its androgen receptor antagonist program to a newly formed company, which Aragon will spin off. Johnson &amp; Johnson will not have an ownership stake in the new company nor retain any rights to these products or programs.&#160; The closing is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act, Aragon's consummation of the spin-off of the newly created company, and other customary closing conditions. The boards of directors of both Johnson &amp; Johnson and Aragon have approved the transaction.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The related press release dated June 17, 2013 is attached as Exhibit 99.1 to this Report.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01  Financial Statements and Exhibits.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d) Exhibits.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibit No.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Description</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Johnson &amp; Johnson press release dated June 17, 2013.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="48%"></td><td width="5%"></td><td width="35%"></td><td width="12%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Johnson &amp; Johnson</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;(Registrant)</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:  June 19, 2013</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/  DOUGLAS K. CHIA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Douglas K. Chia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Secretary</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a201306178-karagonpressrel.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using WebFilings 1 -->
		<!-- Copyright 2008-2013 WebFilings LLC. All Rights Reserved -->
		<title>2013 0617 8-K Aragon Press Release</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s33073fa6fd0d49b1a89defa95618bf9c"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;padding-left:48px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Exhibit 99.1</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="20%"></td><td width="20%"></td><td width="20%"></td><td width="20%"></td><td width="20%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Media:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ernie Knewitz</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kellie McLaughlin</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Phone:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1-732-524-6623</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1-908-927-7477</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Mobile:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1-917-697-2318</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1-609-468-8356</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investor Contacts:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Louise Mehrotra</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stan Panasewicz</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Phone:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1-732-524-6491</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1-732-524-2524</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:180%;padding-bottom:13px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:180%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">FOR IMMEDIATE RELEASE</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">JOHNSON &amp; JOHNSON ANNOUNCES DEFINITIVE AGREEMENT TO ACQUIRE </font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ARAGON PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Late-Stage Prostate Cancer Treatment Strengthens Oncology Pipeline</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">New Brunswick, NJ (June 17, 2013) - Johnson &amp; Johnson announced today a definitive agreement to acquire Aragon Pharmaceuticals, Inc., a privately-held, pharmaceutical discovery and development company focused on drugs to treat hormonally-driven cancers. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The acquisition includes Aragon's androgen receptor antagonist program.  Aragon's lead product candidate is a second generation androgen receptor signaling inhibitor, ARN-509, in Phase 2 development for castration resistant prostate cancer (CRPC).</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Under the terms of the agreement, Johnson &amp; Johnson will make an upfront cash payment of $650 million, plus additional contingent payments of up to $350 million based on reaching predetermined milestones.&#160; The transaction is expected to close in the third quarter of 2013.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Prior to closing, Aragon will transfer all assets other than its androgen receptor antagonist program to a newly formed company, which Aragon will spin off.  Johnson &amp; Johnson will not have an ownership stake in the new company nor retain any rights to these products or programs. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The closing is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act, Aragon's consummation of the spin-off of the newly created company, and other customary closing conditions.  The boards of directors of both Johnson &amp; Johnson and Aragon have approved the transaction. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;The acquisition of Aragon further enhances our leadership in prostate cancer drug development.  ARN-509 complements ZYTIGA&#174; and provides the potential for exciting, novel approaches to treat prostate cancer patients,&#8221; said Peter F. Lebowitz, M.D., Ph.D., Global Therapeutic Area Head, Oncology for Janssen Research &amp; Development, LLC.  &#8220;Prostate cancer is one of our main areas of focus, and we are pleased to be adding ARN-509 to our portfolio.&#8221;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">About Johnson &amp; Johnson</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Caring for the world, one person at a time&#8230;inspires and unites the people of Johnson &amp; Johnson. We embrace research and science -- bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 128,000 employees at more than 275 Johnson &amp; Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.</font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s33073fa6fd0d49b1a89defa95618bf9c"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">About Janssen Research &amp; Development, LLC</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Janssen Research &amp; Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, is headquartered in Raritan, N.J. and has affiliated facilities in Europe, the United States and Asia. Janssen Research &amp; Development is leveraging a combination of internal and external innovation to discover and develop novel medicines and solutions in five distinct therapeutic areas:  Neuroscience, Oncology, Immunology, Infectious Diseases and Vaccines, and Cardiovascular and Metabolism. For more information about Janssen Research &amp; Development, LLC visit </font><font style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;">www.janssenrnd.com</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">#      #     #</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research &amp; Development, LLC and/or Johnson &amp; Johnson. Risks and uncertainties include, but are not limited to, the satisfaction of closing conditions for the acquisition, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act, consummation of Aragon's spin-off transaction, and certain customary closing conditions; the possibility that the transaction will not be completed; general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; and increased scrutiny of the health care industry by government agencies. In addition, if and when the transaction is consummated, there will be risks and uncertainties related to the ability of Janssen Research &amp; Development, LLC and/or Johnson &amp; Johnson to successfully integrate the business of Aragon Pharmaceuticals, Inc. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson &amp; Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2012. Copies of this Form 10-K, as well as subsequent filings, are available online at </font><font style="font-family:Arial;font-size:10pt;color:#0000ff;font-style:italic;text-decoration:underline;">www.sec.gov</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">, </font><font style="font-family:Arial;font-size:10pt;color:#0000ff;font-style:italic;text-decoration:underline;">www.jnj.com</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#32;or on request from Johnson &amp; Johnson. None of the Janssen Pharmaceutical Companies nor Johnson &amp; Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>form8ktemplateimage1.gif
<TEXT>
begin 644 form8ktemplateimage1.gif
M1TE&.#EAM0`O`/<``)H<*8\S/HT\.YDC*9@J-9@X)I8U.ZD:'K<-#K@,&;@5
M&ZL:)ZD<-+H:)[@9,JDB'ZDE**8H-J,T/*<Z-:\R-:XT/*X\,:L\.;0D([0B
M+;,K*KDC)+PC+;PN++<G-K<S.I@Y2*4L0:@X1[HM1;@W1KPX5;-$-H]#38]/
M4)5"0))#2)E`1IY!5)153)=26J9%2*E+4Z=26K=#2+=&5;%23K=46*148;M+
M8;E99ZIE9ZQP<+=D;+YB:[]K:+IR:+1R<\H*&LH5&M$.%M0/&MH(%=T.'=$6
M#]45&\H*(L,2),83*\0;),(;+,L3(\H3+,H:(\H;*\D;,]@))M4)-M87)M,8
M-L,B*L(I+,PC(\HC*\4G-\DR)\DS.],C*M<E-],R-^42&>85)N85-_,<,>,C
M+>8I.NHQ+O$A+_\[/,4;0\8I1<<V1L([5-@G1-DM4-HY1]8Q4-,_5=P^5^,J
M1.@W2.`\5_\S3/<Y5\%$2\=+4\%,6\M!4,Q&6LI,5,Q)6LE56]E$2-A+5]U<
M7<I)8<979-A(8M5:9]%<=]M4=-M><-!E7<IG:,MG=L-T<\)U?,%\?,MQ<,]R
M?,]Z=\A\?M9E:-9H==9U>.9`0.1%6>I36OQ#2?5,7_A/5N=9:>-><O)+:?U7
M:?Y7<^1I:.=H=^9S<.1S>^%_?/)B;/IH=O!Q:_]S=?YT?+1]@,MX@\-]E=5I
M@-MWA.%OB.=VA?UD@/UM@O]OCOUWAOU\D\&`?J^2CLB'A\R4E\N;F=:"B-N,
ME-J7F-JCFM6DIM2PLN>&B>N'E.23AN>6F/B(B_V(EOV2BON6F.6;I?J)H?V9
MI?^=LNJADOJKGNFEI^:JMNBTJOBFJ?ZHM/RTK/ZVN?^LQ/VXQ?^\TNK!N_[#
MNO;&Q/_#P__#RO_*QO[*R__)U?_0Q__4S?[8V?_*X?_;Y?_>\/_CV__RWNCN
M[.SWZ^O\]_/K[/_CY/_DZ_[KY/[KZ__D\__E^O[L\__L^OWTZ_3V]/3U^O3]
M]/3^_?[S\_[T^_W[]/[^_BP`````M0`O`$<(_P#_"1Q(\-^^@P43*D1H\.`^
M@0P52IQ(L:+%BA$;0GQXL:/'CP7Q"?3WCV1)C"7]J03)LN7$?OU.CA08$Z)"
ME?[N<:SILB?(?N$\.#`'[UH60/(6"N27$QZ)!K:0Z:GWCY]`=@=KFBRI[U_,
MF/O:\:QJD*!*JPV[BOR7;VF[@C'C67(PRQZ].U&HW;NWE>Q`?^F>9:$B3L2U
MF.W:<91)L"M!M&];CI6XN.2]N;3DE0,2ALNU>,F.'"DG4%ZZ`M/NO<O0!%6$
M;.^>@A)G@%LZ3E3HH.KU;I4"#N*0$4IG38H86^?>R:B"R9Z]?_>0K;G'#YL#
M)[8BB`/W((LM>?SD\?^(\ND;+"U>UI0KETU*FW/U.CW!0$D>O"Y!CJ7+J:X8
MC7?Q'$/%&*@P4@\U01#6B@[Q7'-`%JA\$`XX&"R!BC@@1)..)D<T`-\U3CCA
M#4GVG"/"+_*\T\<1:&!R"SR5!+%%//S4N%!E_O`32R7WQ),-`=)095)E/A5I
MI%<8AG./>#/,4Q-:1T8I957U,#7EE5+6R%=?6'8)4D9>AAFE0QN):29E'*E4
M3R\&7"-.!.$L51"13FEQ#@B^5'EFD:J)4,DYK3@"3U(V#:15=!XHTPP(>NY9
M9'P-+&*?+**5PX\]VO#AP2+7>("*!\W,,T\U40!Q3#SQ=-*`![`(!,\Q"EC_
M@4.5U3@0!03R^"./.`#,4,Y>U9``A0+0^&!"*A^(D\T,'BQ``3?\S*-&%5HT
M0U5*CNV58S8>/'"-/.=0084I\=@S#S(1&"".''5T(L,Y\)CSB115O'-/-FH$
M<<4[_=23#1RW7K.D'PTTH$Q2\BP2P37JW'-.(<,J`@X$J%B@3#FRC."`%8+<
M4P\S:52Q!CR%_I503CG6,\@GMC10B9/]R!..#!FL44HY7_7S`PPX>[7+"\I<
MRT\U*4QC53_?R*"'."6]$P,(O3#%3D[#D!#!#,90)U`Y*.0`#TSW_'+U.57A
M!-X]P`2#5HW6<%%-!A"(\U4YQT10`2'4H.4O"]58_YG.'S*$8Q4_Y\3`"#HP
MR?/("\U\/<\R(.``SUGW@$-(!'Z2HPX[7BTC0C9,^7,.#"+XPI1C%?FS#`&_
MIJ/N9(Z>Z4]LF=T#BR5\C>0/ZK'W[OOO)P,O_/#$HU2\F&$1>1&9QW?$D?()
M*<]\\Q8YI!(\XO!P@C!04J1K-3M$8R/U-U;%3SW+/#W/13F50PPC[WA%_D#0
M\R..`VNHHTX@6A!*_V(P.9\C/%4.`D0C=V!J7HX\X8%KI,,9#CC@[BA3$G%$
MH0KD,,8+_#<_W0VD'J6`P"+@48]A4"$+\1-(/7*RE[TL!1X4:``=""$/>6AK
M(-'*U4!0M15^W#!'50'/.__``Z5ZS*.(5>+'DQCCCX><8P`9`!T\&K"$K%GE
M+#;4&E/B@0SCD$`OJ@'/0-Y1HZ.QT'_]@`<_PE(5Y]3#B/78DA++2!(EOE$C
M%N%',Z)`@G/<`T%':`8U"("*(E!!'OW(!B,T`($:4$,<6F@`,LHA`V5X00J@
MF$<]:G`,301A#>=`AB=0`04(G$,>G8J"%.[@@5*<8Q1,6$4][&$,&;Q!"]Z0
M!P0Y\,@1D$J2H?-'/08%CV8,`!;O>,<%,*",\ZTA"&\0QR`*,8<$4.,=YX"%
M#"Y`@&-<0T!->$<T<-",(P0A'4/S90.TH`QQ5(`:5J#"*H98B#(480B@(($X
MM"'_!2C\2AR'B(,'+'&.<P#B"&8H1R5D08LP=(&,'6%A-B(PBF9(@0JC$"(7
M@.`%6V@#&9MZXSD\@`0FG,-<'VB"%V"0*WD(8@E1^(X\5I$`)>P!1=58`S.T
M4`D;4F,)5*C6-40!`67$XQ[7:``0M)".>Y#C`&&X@QJ88<-J,"($`/#`!_+0
MC&[<(QPU($$V[$`%")3#.;:(0A+>4(UF=,(#XG@C,:8@!EF0D!I'"(,#JI&3
M;$1!"6H`4#@R`(0YC$`<Y0":%@9`CAY]@0P-0$4VFF$%I/1C'GRXZ##D`4(@
MC"$4(G@'E[B$PWJT0A?IN`8$7D$/JQPD)TH42&2\TH^<_]#6'FUQ53]<6S8Q
MCD1K\CM)/^@Q%IB0I2M,42)8%K,5?\#$'"DHQSLN)SB$Q(PI8'D+"R<H/Y.@
MA2?M8"%!.+@3X\:DCJ49B#M@`CN*V$\$XMA+,TKPG`Y&21Z5,`1?W@&#O)V7
MM/9MB3_N-P4WA!;``6:)KCK1AB@P(&LD@5Z"C3?AWJVDPE*2,(:/=.&$Z(-W
M&_Y2B(FGX0`G<,1G@EZ)$WQB%!^)>2UV\?)6/)$8RY@@"61>>SO($.K4J!X<
MK(B/DX)@ZNTCMSXLXS^N95SEP?9L:YDP0QY2(V/,H!J54-M%]$@"600@&[NM
M\-3N48X81"(;(G#21IP\NQGPP?\0+K!*E"N<(W1=$QD,(%N'2Z;$I(+B'#7(
MDVMI##S"B6`&!7V!+K2VW)/%8PU1^$8STER6^2DO9H2(PBWBD0X.<.$>(UG,
M3J@4@PRLHAH2*,=6;%QH;SA`#35$15[XPCG8/02I54!".1HQB6L%6"4<J8<R
M(/"N>33C"5_0R=H&`FKHJ`8`6K#%&AHW1U`_!"87UI9(C*N/:R^E)CSA2\RN
M\EOO&NHQ\;@`!YIAKC8X02\=+NY>BI&$,@C'MUD9R='ZX0Z<R&DCZZ`)3283
M;IH0"L0F^R!1(<%965#A"4F!R>-:8(U%U*!O(LT`%1KPC7240Q("B-,^PE,*
M"02C-,C_$`$N",4/5FRC1SER7PU:,(X>]$!P_<CF#!S!67LLZP4].YD_WO*-
M#T#@&H1;PA.,H=QZE",'/_!&#'1A*7[``QEBD((L4D0-&5#"1D,3`0S(V(\R
M`_UHXK#!"O71+RROH!FPJ`$PFHI*'+S`&BJ91RM"T(Q&5X0?J&A`#6JHC"`<
MX5OBF$$3J'"-<HR@%IOP`#)NH(8D4,$6Q-&"N%!1CWZ(XP!DH$*3X#$#+U"!
M`[^2AR&TL-==$\(65"A#.:@Q`64`8@TBN`4RM,!,>!!C#E)P`C*NZ&]^4,,'
MX=`,`#!PC7J<`PI4$`4VS],`0YPC%&X`*24J00(M2&$.\2A'_Z;#@(!?U:,2
M59`"!XQJC#<@H374R48#G@`(XDC@%F2U!CGP@`I5:``/?N`,;R`$E[`>)9!^
M7N`DN14]9E$.0I$-\F`-05`$F+`PQP`&9!`__5(.)@`-\7`.&;`$JW`,E%`.
M'T`%J'`.&E0.FD`%@/`-8J4*#:`!ZT$(R-!%4H`<[_`"4&$/,%%,'K`DU>`!
M#=`,J$`+WX`!&W`,6Q(.E2`".=`+V;`&?W`.Z4`*#7`*LQ0(*L4%B2`.98`%
M1@5DZ3`,,E`.`7($9%`.*B`.S1`$02!=+U`-UX`!DH0*J^`-&Q`$J``/U"!6
M9Q`&56`.QE8%2<`7=G$.;&`,*8('1O^`!M4@`N5`"4>`!3128V9!9B.@'NE`
M!D6`"O;"#0F"#/`P#Q%8`$T%#QK7!'9U#A60!:`0",1P#^F0">+B`>60#K:0
M!0TP4=E`25Z`!(8P1)3`42=50Y1`"4*H>5JP6>4``4&`#.+@`O+@"PX`!]5P
M#K8`!1XP"HLP`U$0!<0`#[:P!!#05.>`"53P`4-$BR\`">GP#LH@!5*@3_70
M#%1`!,X``DT5#AR0!%IP#._PC$^`"J/`"/)0#%_0!0VD&5#0!,-`(_50#1'P
M#?;1!T-P!*`$(UV`!>G`"[G`/OH@A!'0!F4`!91`%4/3`%[@!%'@`3+P#3XX
M#P,0;>92#S/_4##?4"/R0`D+T$?A<0P.H`5ZP!?*L`:ND3<Y00FQH@4'($(T
M<@_>,`!<@`RY$@\0X`1SP`;HX$-+`@\%I0P\D"M\40YKT`1B4`40(),EX@=,
M\)+-(@MOU`_+D`9J(`XU0@T*@%'GD!/AP`#1)D01$`4-@`WS``\&@`P?,'A[
M<0T*L$X-D`$=@'27<@-1H`6J)@_#$(QJT`Q68A8W$7,S$!P>@`,^&!-+\@[P
M$#^+043?!0_/816<Y5M5,41Z`AY)Q&SW4(J=!Q:T%5NU%1Z^Y@]3$TQPL0BB
M4`Y6\PU4\1##-$16H1A>X4--I`_AH4.#(P_.<2C\`A/.X8-^L63SYH`.<52=
MYZ-&,O%&068RRN-\('!4$P4+1V00B3%;]+D5N?,5E28_UG-A/#$]E49P,=%M
M,U$F".<5]N`*NA`/\(`#$="7-39R.$&@<Y(2:[8/N5.@`G&@.%006[%C]),0
M\C`#S;`7U!`"I!%<-S81>C0#3`$/AM-Y,T%H+N8/UR`"?G0/E8`,(+JB?\$/
M;&`+>R$.K&,2>^:C"G$/T1`"V%`.C]`*Y]"C2*HK:X`)Y_`-ZI*A2&H1.8((
M:5`(VM`]6WH30\,`:H`,*Q1A8QJB%,%J:VH0^M`.'/JF=%JG=OIK$U%D&Q80
"`#L_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
